CRF is proud to produce its first-ever Technology and Heart Failure Therapeutics conference, THT 2022. Given the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart failure.
THT 2022 is the conference that focuses on technologies that will fill existing gaps.
Covering a full range of updates on the current status of drug- and device-based treatments for heart failure across the spectrum, LV ejection fractions, and a late-breaking pivotal studies that have not yet appeared in treatment guidelines, THT 2022 is an immersive experience in the latest innovations that practitioners can put into practice for treating heart failure.
With unlimited opportunities for learning and global engagement, THT 2022 offers a future-oriented view of the pipeline for heart failure therapeutics, with a focus on in-development technologies (drugs, devices, monitoring strategies) that are currently in clinical trials — as well as an overview of the rapid advances in artificial intelligence and machine learning and how these technologies will transform the care of heart failure patients in the near future.